XARELTO® is the only new oral anticoagulant with FDA approval in this indication Raritan, NJ (July 1, 2011) /PRNewswire/ - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug ...

FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events RARITAN, NJ, November 2, 2012 – Janssen Pharmaceuticals, Inc.

XARELTO (rivaroxaban) 20mg tablets Janssen Pharmaceuticals announced FDA approval of Xarelto (rivaroxaban) tablets for the prevention of deep vein thrombosis (DVT) that may lead to a pulmonary ...

Pexidartinib is an oral small molecule that is believed to work by inhibiting colony stimulating factor-1 receptor (CSF1R). Both doses of Xarelto (10mg and 20mg) were superior to aspirin (100mg) in ...

NEW YORK (AP) — Johnson & Johnson’s Xarelto received an expanded indication as the Food and Drug Administration on Friday approved the blood thinner both to treat and to reduce the risk of recurrence ...

Please provide your email address to receive an email when new articles are posted on . Janssen Research & Development announced the launch of three new clinical trials to evaluate rivaroxaban for the ...

Dear Dr. Roach: I am an 81-year-old female who has been on Xarelto for years due to my deep vein thrombosis (DVT). I also have an inferior vena cava (IVC) filter. I read that low-dose aspirin (325 mg) ...

Aurobindo has obtained the Food and Drug Administration’s green light for rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto. Rivaroxaban tablets are used to reduce the risk of ...

Raritan, NJ (July 1, 2011) - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets), a novel, once-daily, oral ...